US HMOs Using 1984 Law As Malpractice Defense

25 November 1996

US health maintenance organizations including US Healthcare, Kaiser Permanente, Prudential and Pacificare are using the 1984 Employee Retirement Income Security Act to protect themselves against malpractice suits, reports the New York Times. The HMOs say they cannot be held responsible for quality of care provided through employer-sponsored health plans, because their care decisions are administrative rather than medical.

Labor Secretary Robert Reich, who enforces the law, replies that this argument is absurd since it would deprive many consumers of the right to sue for injuries caused by an HMO's negligence. The Clinton Administration is thinking about legislation to clarify the rights of those covered by HMOs; in the last three years, the NYT noted, the federal government has filed friend-of-the-court briefs disagreeing with HMOs in six cases.

A Pacificare spokesman said its contract is with doctors and hospitals, and any litigation should be directed towards them, not the HMO. Courts have split on this issue; recently, it seems patients have a better chance of winning against HMOs when they charge substandard care rather than an outright denial of health plan benefits. A spokesman for the American Medical Association said HMOs are shifting all the risk of patient care to doctors, even though they can force doctors to change their clinical decisions by threatening to terminate their contracts.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight